A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Nature Reviews Neuroscience

• Publication date

  2015-08-05

• Fields of study

  Biology, Medicine, Psychology

• Identifiers
  DOI 10.1038/nrn3983PMID 26243569PMCID PMC4678594
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• What is a case study?

  2017cited by this paper
• Faculty Opinions recommendation of The French series of autosomal dominant early onset Alzheimer's disease cases: mutation spectrum and cerebrospinal fluid biomarkers.

  2016cited by this paper
• Faculty Opinions recommendation of ABCG1 influences the brain cholesterol biosynthetic pathway but does not affect amyloid precursor protein or apolipoprotein E metabolism in vivo.

  2016cited by this paper
• APP Metabolism Regulates Tau Proteostasis in Human Cerebral Cortex Neurons

  2015cited by this paper
• Serum NGAL is Associated with Distinct Plasma Amyloid-β Peptides According to the Clinical Diagnosis of Dementia in Down Syndrome

  2015cited by this paper
• Age dependence of brain β-amyloid deposition in Down syndrome

  2015cited by this paper
• Estimates of the live births, natural losses, and elective terminations with Down syndrome in the United States

  2015cited by this paper
• N-butylidenephthalide Attenuates Alzheimer's Disease-Like Cytopathy in Down Syndrome Induced Pluripotent Stem Cell-Derived Neurons

  2015cited by this paper
• Accelerated epigenetic aging in Down syndrome

  2015cited by this paper
• “Noncognitive” symptoms of early Alzheimer disease

  2015cited by this paper
• Brief Report: Isogenic Induced Pluripotent Stem Cell Lines From an Adult With Mosaic Down Syndrome Model Accelerated Neuronal Ageing and Neurodegeneration

  2015cited by this paper
• Dysfunction of Wnt signaling and synaptic disassembly in neurodegenerative diseases

  2014cited by this paper
• Polymorphisms in BACE2 may affect the age of onset Alzheimer's dementia in Down syndrome

  2014cited by this paper
• Rare autosomal copy number variations in early-onset familial Alzheimer’s disease

  2014cited by this paper
• A prospective 14-year longitudinal follow-up of dementia in persons with Down syndrome.

  2014cited by this paper
• Toward onset prevention of cognitive decline in adults with Down syndrome (the TOP-COG study): study protocol for a randomized controlled trial

  2014cited by this paper
• Domains of genome-wide gene expression dysregulation in Down’s syndrome

  2014cited by this paper
• Sorting nexin 27 regulates Aβ production through modulating γ-secretase activity.

  2014cited by this paper
• Molecular Mechanisms of Cellular Cholesterol Efflux*

  2014cited by this paper
• A distinct subfraction of Aβ is responsible for the high‐affinity Pittsburgh compound B‐binding site in Alzheimer's disease brain

  2014cited by this paper
• Microglial priming in neurodegenerative disease

  2014cited by this paper
• Role of astroglia in Down’s syndrome revealed by patient-derived human-induced pluripotent stem cells

  2014cited by this paper
• Frontal white matter integrity in adults with Down syndrome with and without dementia.

  2014cited by this paper
• Cognitive functioning in relation to brain amyloid-β in healthy adults with Down syndrome.

  2014cited by this paper
• Progressive myoclonus epilepsy in Down syndrome patients with dementia

  2014cited by this paper
• Large APP locus duplication in a sporadic case of cerebral haemorrhage

  2014cited by this paper
• The Amyloid Precursor Protein Controls Adult Hippocampal Neurogenesis through GABAergic Interneurons

  2014cited by this paper
• REST and Stress Resistance in Aging and Alzheimer’s Disease

  2014cited by this paper
• Amyloid precursor protein and neural development

  2014cited by this paper
• Modelling and rescuing neurodevelopmental defect of Down syndrome using induced pluripotent stem cells from monozygotic twins discordant for trisomy 21

  2013cited by this paper
• Translating Dosage Compensation to Trisomy 21

  2013cited by this paper
• Seizures and epileptiform activity in the early stages of Alzheimer disease.

  2013cited by this paper
• Mitochondria impact brain function and cognition

  2013cited by this paper
• Evidence supporting an intentional Neandertal burial at La Chapelle-aux-Saints

  2013cited by this paper
• Overexpression of Down Syndrome Cell Adhesion Molecule impairs precise synaptic targeting

  2013cited by this paper
• Usp16 contributes to somatic stem cell defects in Down syndrome

  2013cited by this paper
• Defective Mitochondrial Function In Vivo in Skeletal Muscle in Adults with Down’s Syndrome: A 31P-MRS Study

  2013cited by this paper
• Fused in Sarcoma (FUS) gene mutations are not a frequent cause of essential tremor in Europeans.

  2013cited by this paper
• The population prevalence of Down’s syndrome in England and Wales in 2011

  2013cited by this paper
• Deficits in human trisomy 21 iPSCs and neurons

  2013cited by this paper
• A Longitudinal Study

  2013cited by this paper
• Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial.

  2013cited by this paper
• Reduction of Synaptojanin 1 Accelerates Aβ Clearance and Attenuates Cognitive Deterioration in an Alzheimer Mouse Model*

  2013cited by this paper
• Atypical aging in Down syndrome.

  2013cited by this paper
• Trends in maternal age distribution and the live birth prevalence of Down’s syndrome in England and Wales: 1938–2010

  2013cited by this paper
• Abnormal brain synchrony in Down Syndrome☆

  2013cited by this paper
• Evidence that PICALM affects age at onset of Alzheimer's dementia in Down syndrome

  2013cited by this paper
• Down’s syndrome, neuroinflammation, and Alzheimer neuropathogenesis

  2013cited by this paper
• Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease

  2013cited by this paper
• Analysis of Copy Number Variation in Alzheimer’s Disease in a Cohort of Clinically Characterized and Neuropathologically Verified Individuals

  2012cited by this paper
• Analysis of copy number variation in Alzheimer's disease: the NIALOAD/ NCRAD Family Study.

  2012cited by this paper
• A Human Stem Cell Model of Early Alzheimer’s Disease Pathology in Down Syndrome

  2012cited by this paper
• Reduction of Synaptojanin 1 Ameliorates Synaptic and Behavioral Impairments in a Mouse Model of Alzheimer's Disease

  2012cited by this paper
• Trisomy for synaptojanin1 in Down syndrome is functionally linked to the enlargement of early endosomes.

  2012cited by this paper
• A genome-wide study shows a limited contribution of rare copy number variants to Alzheimer's disease risk

  2012cited by this paper
• The French Series of Autosomal Dominant Early Onset Alzheimer's Disease Cases: Mutation Spectrum and Cerebrospinal Fluid Biomarkers

  2012cited by this paper
• Cognitive reserve in ageing and Alzheimer's disease.

  2012cited by this paper
• BACE2 expression increases in human neurodegenerative disease.

  2012cited by this paper
• Role of common and rare APP DNA sequence variants in Alzheimer disease

  2012cited by this paper
• Genetic and environmental vulnerabilities in children with neurodevelopmental disorders

  2012cited by this paper
• Down Syndrome and Dementia: Seizures and Cognitive Decline

  2012cited by this paper
• Size frequency distributions of β-amyloid (Aβ) deposits: a comparative study of four neurodegenerative disorders.

  2012cited by this paper
• Trisomy correction in Down syndrome induced pluripotent stem cells.

  2012cited by this paper
• Duplication of amyloid precursor protein (APP), but not prion protein (PRNP) gene is a significant cause of early onset dementia in a large UK series

  2012cited by this paper
• Incidence of new-onset seizures in mild to moderate Alzheimer disease.

  2012cited by this paper
• Oxidative Stress and Memory Decline in Adults with Down Syndrome: Longitudinal Study

  2012cited by this paper
• Seizures and Epilepsy in Alzheimer's Disease

  2012cited by this paper
• Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound B

  2012cited by this paper
• Behavioural Excesses and Deficits Associated with Dementia in Adults who have Down Syndrome

  2011cited by this paper
• Neuronal activity regulates the regional vulnerability to amyloid-β deposition

  2011cited by this paper
• Down syndrome and dementia: A randomized, controlled trial of antioxidant supplementation

  2011cited by this paper
• Positron emission tomography of brain β-amyloid and τ levels in adults with Down syndrome.

  2011cited by this paper
• Neuropathological alterations in Alzheimer disease.

  2011cited by this paper
• APP Transgenic Mice: Their Use and Limitations

  2011cited by this paper
• TDP-43 pathological changes in early onset familial and sporadic Alzheimer’s disease, late onset Alzheimer’s disease and Down’s Syndrome: association with age, hippocampal sclerosis and clinical phenotype

  2011cited by this paper
• SOD1 (Copper/Zinc Superoxide Dismutase) Deficiency Drives Amyloid β Protein Oligomerization and Memory Loss in Mouse Model of Alzheimer Disease*

  2011cited by this paper
• Mutation screening of patients with Alzheimer disease identifies APP locus duplication in a Swedish patient

  2011cited by this paper
• A perfect storm: Converging paths of epilepsy and Alzheimer’s dementia intersect in the hippocampal formation

  2011cited by this paper
• Using Positron Emission Tomography and Carbon 11–Labeled Pittsburgh Compound B to Image Brain Fibrillar (cid:2) -Amyloid in Adults With Down Syndrome Safety, Acceptability, and Feasibility

  2011cited by this paper
• Alzheimer's disease in Down's syndrome: Clinicopathologic studies

  2011cited by this paper
• Microglial pathology in Down syndrome

  2011cited by this paper
• Using positron emission tomography and Carbon 11-labeled Pittsburgh Compound B to image Brain Fibrillar β-amyloid in adults with down syndrome: safety, acceptability, and feasibility.

  2011cited by this paper
• P1‐246: Genome‐Wide Association Analysis Identifies Novel Loci Associated with the Onset Age Among Cases with Late‐Onset Alzheimer's Disease

  2011cited by this paper
• Link Between DYRK1A Overexpression and Several-Fold Enhancement of Neurofibrillary Degeneration With 3-Repeat Tau Protein in Down Syndrome

  2011cited by this paper
• Association of variants within APOE, SORL1, RUNX1, BACE1 and ALDH18A1 with dementia in Alzheimer's disease in subjects with Down syndrome.

  2011cited by this paper
• Reversal of autophagy dysfunction in the TgCRND8 mouse model of Alzheimer's disease ameliorates amyloid pathologies and memory deficits.

  2011cited by this paper
• Meta-analysis of heterogeneous Down Syndrome data reveals consistent genome-wide dosage effects related to neurological processes

  2011cited by this paper
• Dementia in Older Adults With Intellectual Disabilities—Epidemiology, Presentation, and Diagnosis

  2010cited by this paper
• The First Confirmed Case of Down Syndrome with Dementia with Lewy Bodies

  2010cited by this paper
• Comparison of intima-media thickness of the carotid artery and cardiovascular disease risk factors in adults with versus without the Down syndrome.

  2010cited by this paper
• Cerebral amyloid angiopathy as a cause of an extensive brain hemorrhage in adult patient with Down's syndrome - a case report.

  2010cited by this paper
• Senile myoclonic epilepsy: delineation of a common condition associated with Alzheimer's disease in Down syndrome.

  2010cited by this paper
• The relationship between acquired impairments of executive function and behaviour change in adults with Down syndrome.

  2010cited by this paper
• Oligomeric Dop1p is Part of the Endosomal Neo1p‐Ysl2p‐Arl1p Membrane Remodeling Complex

  2010cited by this paper
• In vivo effects of APP are not exacerbated by BACE2 co-overexpression: behavioural characterization of a double transgenic mouse model

  2010cited by this paper
• Early Age at Menopause is Associated with Increased risk of Dementia and Mortality in Women with Down Syndrome

  2010cited by this paper
• Mutant WDR36 directly affects axon growth of retinal ganglion cells leading to progressive retinal degeneration in mice

  2010cited by this paper
• Upregulation of three Drosophila homologs of human chromosome 21 genes alters synaptic function: Implications for Down syndrome

  2009cited by this paper
• Age‐dependent dysregulation of brain amyloid precursor protein in the Ts65Dn Down syndrome mouse model

  2009cited by this paper
• DYRK1A genetic variants are not linked to Alzheimer's disease in a Spanish case-control cohort

  2009cited by this paper

• Large-scale APP duplication in early-onset Alzheimer's disease without cerebral amyloid angiopathy: A case report

  2026cites this paper
• DNA methylation and the APP gene: dietary influences in the context of Alzheimer’s disease—a mini review

  2026cites this paper
• Trisomy 21 Impairs Synchronized Activity in Human Down Syndrome Cortical Excitatory Neuron Networks

  2026cites this paper
• Apolipoprotein E abundance is elevated in the brains of individuals with Down syndrome-Alzheimer’s disease

  2025cites this paper
• Targeting Amyloid Pathology in Early Alzheimer’s: The Promise of Donanemab-Azbt

  2025cites this paper
• Enhancing protein O-GlcNAcylation in down syndrome mice mitigates memory dysfunctions through the rescue of mitochondrial bioenergetics, stress responses and pathological markers

  2025cites this paper
• Telomere Biology, Erosion, and Age-Related Conditions: Insights from Down Syndrome and Other Telomere-Associated Disorders

  2025cites this paper
• Interferon signaling modulates Down syndrome-associated Alzheimer’s disease pathology in a mouse model

  2025cites this paper
• APP antisense oligonucleotides are effective in rescuing mitochondrial phenotypes in human iPSC‐derived trisomy 21 astrocytes

  2025cites this paper
• Characterization of neurodegenerative pathologies in adult and pediatric subjects with Down syndrome

  2025cites this paper
• Amyloid neuropathy, tauopathy, decreased cholinergic and dopaminergic neurons, long-term memory and motor deficits, and sleep disturbance in motopsin deficient mice.

  2025cites this paper
• The association between cardiorespiratory fitness and resting‐state functional connectivity in adults with Down syndrome

  2025influential citation
• Resistance and resilience to Alzheimer's disease in Down syndrome

  2025cites this paper
• Lifestyle Composite and Resilience to Alzheimer's Disease Pathology in Down Syndrome

  2025cites this paper
• Impaired BDNF-TrkB trafficking and signalling in Down syndrome basal forebrain neurons

  2025cites this paper
• Biomarker identification for Alzheimer’s disease through integration of comprehensive Mendelian randomization and proteomics data

  2025cites this paper
• HSPA13 gene and microRNA-155: relationship between Down syndrome and Alzheimer’s disease

  2025cites this paper
• Mitochondrial Imbalance in Down Syndrome: A Driver of Accelerated Brain Aging?

  2025cites this paper
• Selective chr21 homolog silencing reveals polymorphisms influence the epigenetic silencing and functional dosage of RWDD2B

  2025cites this paper
• Impact of dietary intervention and supplementation on the physiological profile of individuals with down syndrome

  2025cites this paper
• Diagnostic Paper‐Pencil Instruments for Dementia in People With Intellectual Disability: Scoping Literature Review

  2025cites this paper
• The placental effects of trisomy for human chromosome 21 orthologs in four mouse models of Down syndrome

  2025cites this paper
• Deciphering ETS2: An indispensable conduit to cancer.

  2025cites this paper
• Epigenetic and transcriptomic alterations precede amyloidosis in the Alzheimer’s disease AppNL-G-F knock-in mouse model

  2025cites this paper
• Longitudinal study of body mass index in relation to Alzheimer's disease pathology and symptomatology in Down syndrome

  2025cites this paper
• The Down Alzheimer Barcelona Neuroimaging Initiative (DABNI) and its contributions to understanding Alzheimer's disease in Down syndrome: A decade of discovery

  2025cites this paper
• The cholinotrophic system in Down syndrome.

  2025cites this paper
• Genome‐wide association analyses identify candidate loci for amyloid imaging and plasma biomarkers in adults with Down syndrome

  2025cites this paper
• Salivary lactoferrin levels in Down Syndrome: a case-control study

  2025cites this paper
• NCAM2 promotes targeting of APP from the cell surface to BACE1-containing recycling endosomes.

  2025cites this paper
• Antibody concentration and function following SARS-CoV-2 vaccination decrease with age in adults and children with Down syndrome.

  2025cites this paper
• Factors Associated With Alzheimer's Dementia Diagnosis and Survival in Down Syndrome

  2025cites this paper
• Eye Tracking as a Tool for Detecting Alzheimer's Disease in People With Down Syndrome

  2025cites this paper
• Single-nucleus analysis reveals oxidative stress in Down syndrome basal forebrain neurons at birth

  2025cites this paper
• Preliminary investigation of obstructive sleep apnea and Alzheimer’s disease in down syndrome

  2025cites this paper
• Neuropsychological profile of an adult with Down syndrome-Klinefelter syndrome

  2025cites this paper
• Polyamine biosynthesis dysregulation in Alzheimer’s disease and Down syndrome cellular models

  2025cites this paper
• Development of Alzheimer’s disease in Down syndrome

  2025cites this paper
• Dural ectopic lymphatic structures accumulate during aging and exhibit dysregulation in neurodegenerative diseases

  2025cites this paper
• Regional differences in astrocytic Aquaporin-4 protein levels and distribution in aging and Alzheimer's disease in down syndrome.

  2025cites this paper
• T-cell responses to SARS-CoV-2 vaccinations in adults with Down syndrome – a prospective cohort study

  2025cites this paper
• Plasma p-tau217 as a biomarker of Alzheimer’s disease pathology in individuals with Down syndrome

  2025cites this paper
• Next-generation neurotherapeutics: mechanistic insights on monoclonal antibodies in Alzheimer's disease.

  2025cites this paper
• Development of Molecular Neuropathology in Down Syndrome across the Lifespan

  2025cites this paper
• A myeloid trisomy 21-associated gene variant is protective from Alzheimer’s disease

  2025cites this paper
• Factors Affecting Macro-Structural Development in the Cerebral Cortex: The Potential Role of Tissue Removal Through Pruning and Apoptosis

  2025cites this paper
• Longitudinal investigation of gait and Alzheimer's disease in adults with Down syndrome

  2025cites this paper
• Apolipoprotein E abundance is elevated in the brains of individuals with Down syndrome–Alzheimer’s disease

  2025cites this paper
• Unraveling the Genetic and Phenotypic Complexity of Down Syndrome from Trisomy 21 to Comorbid Conditions

  2025cites this paper
• Staging of Alzheimer's disease progression in Down syndrome using mixed clinical and plasma biomarker measures with machine learning

  2025cites this paper
• White matter trajectories in Down syndrome and Alzheimer's disease: Insights from diffusion tensor–based morphometry

  2025cites this paper
• Disease‐specific neuropathological alterations of the locus coeruleus in Alzheimer's disease, Down syndrome, and Parkinson's disease

  2025cites this paper
• miR155 triplicated in Down syndrome regulates hippocampal GABAergic neurogenesis in Alzheimer’s disease

  2025cites this paper
• Primary age-related tauopathy

  2025cites this paper
• Early-Onset Alzheimer’s disease and amyloid precursor protein gene mutations

  2025cites this paper
• Investigating the eye in Down syndrome as a window to Alzheimer’s disease: the REVEAL protocol – a clinical cross-sectional study

  2025cites this paper
• Cholinotrophic basal forebrain connectome dysfunction in Down syndrome with and without dementia

  2025cites this paper
• Genetically determined Alzheimer's disease research advances: The Down Syndrome & Autosomal Dominant Alzheimer's Disease 2024 Conference

  2025influential citation
• Single‐nucleus analysis reveals oxidative stress in Down syndrome basal forebrain neurons at birth

  2025cites this paper
• Epigenetic and Transcriptomic Alterations Precede Amyloidosis in the Hippocampus of the Alzheimer’s Disease AppNL-G-F Knock in Mouse Model

  2025cites this paper
• Cognitive markers for the distinction between asymptomatic and prodromal Alzheimer's disease in Down syndrome: Correlations with volumetric brain changes

  2025cites this paper
• A Comprehensive Review on Potential Molecular Drug Targets for the Management of Alzheimer's Disease.

  2024cites this paper
• In vivo quasi-elastic light scattering detects molecular changes in the lenses of adolescents with Down syndrome.

  2024cites this paper
• Data-driven modelling of neurodegenerative disease progression: thinking outside the black box

  2024cites this paper
• The role of ATP‐binding cassette transporter G1 (ABCG1) in Alzheimer's disease: A review of the mechanisms

  2024cites this paper
• A Trisomy 21-linked Hematopoietic Gene Variant in Microglia Confers Resilience in Human iPSC Models of Alzheimer’s Disease

  2024cites this paper
• RNA m6A Methylation and Alzheimer's Disease: Current Evidence and Future Perspectives

  2024cites this paper
• Oxidative damage in neurodegeneration: roles in the pathogenesis and progression of Alzheimer disease.

  2024cites this paper
• The hypothalamic–pituitary–gonadal axis and the enigma of Alzheimer disease sex differences

  2024cites this paper
• CaMKII mechanisms that promote pathological LTP impairments.

  2024cites this paper
• Total cell N-glycosylation is altered during differentiation of induced pluripotent stem cells to neural stem cells and is disturbed by trisomy 21

  2024cites this paper
• Autoimmune Thyroid Disease in Patients with Down Syndrome—Review

  2024cites this paper
• Genetic interactions and co-operating effects of non-HSA21 genes on the phenotypic variability in down syndrome

  2024cites this paper
• What Can We Learn About Alzheimer's Disease from People with Down Syndrome?

  2024cites this paper
• Extra virgin olive oil beneficial effects on memory, synaptic function, and neuroinflammation in a mouse model of Down syndrome

  2024cites this paper
• Understanding perspectives and research trends in Down syndrome neuropathogenesis: A bibliometric analysis.

  2024cites this paper
• Leucettinib-21, a DYRK1A Kinase Inhibitor as Clinical Drug Candidate for Alzheimer’s Disease and Down Syndrome

  2024cites this paper
• Comparison between DSQIID total / sub-item scores and plasma p-tau elevation in adults with Down’s syndrome

  2024cites this paper
• Exploring crystallized and fluid intelligence in down syndrome using graph theory

  2024cites this paper
• The mTOR Pathway: A Common Link Between Alzheimer’s Disease and Down Syndrome

  2024cites this paper
• Physiopathological mechanisms underlying Alzheimer’s disease: a narrative review

  2024cites this paper
• NF-κB in Alzheimer’s Disease: Friend or Foe? Opposite Functions in Neurons and Glial Cells

  2024cites this paper
• Amyloid-independent pathogenesis for Alzheimer’s disease: implications for drug design

  2024cites this paper
• Amyloid-β peptide signature associated with cerebral amyloid angiopathy in familial Alzheimer’s disease with APPdup and Down syndrome

  2024cites this paper
• It’s good to know what to BACE the specificity of your inhibitors on

  2024cites this paper
• Review of valiltramiprosate (ALZ-801) for the treatment of Alzheimer’s disease: a novel small molecule with disease modifying potential

  2024cites this paper
• Integrative multi-omic analysis reveals conserved cell-projection deficits in human Down syndrome brains.

  2024cites this paper
• A dynamic in vitro model of Down syndrome neurogenesis with trisomy 21 gene dosage correction

  2024cites this paper
• Cognitive and functional performance and plasma biomarkers of early Alzheimer's disease in Down syndrome

  2024cites this paper
• IgG1 glycosylation highlights premature aging in Down syndrome

  2024cites this paper
• From understanding to action: Exploring molecular connections of Down syndrome to Alzheimer's disease for targeted therapeutic approach

  2024cites this paper
• The cGAS-STING-mediated ROS and ferroptosis are involved in manganese neurotoxicity.

  2024cites this paper
• Altered Brain Cholesterol Machinery in a Down Syndrome Mouse Model: A Possible Common Feature with Alzheimer’s Disease

  2024cites this paper
• Alzheimer-Demenz bei Menschen mit einem Down-Syndrom

  2024cites this paper
• Exploring peripheral fluid biomarkers for early detection of Alzheimer's disease in Down syndrome: A literature review

  2024cites this paper
• Patients With Down Syndrome and Total Hip and Total Knee Arthroplasty: Outcome Measures Show Increased Risk of Perioperative Complications

  2023cites this paper
• Identifying the joint signature of brain atrophy and gene variant scores in Alzheimer's Disease

  2023cites this paper
• Alzheimer's polygenic risk scores are associated with cognitive phenotypes in Down syndrome

  2023cites this paper
• Common mental health disorders and cognitive decline in a longitudinal Down syndrome cohort

  2023cites this paper
• AT(N) biomarker profiles and Alzheimer's disease symptomology in Down syndrome

  2023cites this paper